57 studies found for:    gdc-0449
Show Display Options
Rank Status Study
1 Unknown  The Purpose of This Study is to Determine The Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Conditions: Basal Cell Nevus Syndrome;   Gorlin Syndrome
Intervention: Drug: GDC-0449
2 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib;   Drug: Bevacizumab;   Drug: Modified FOLFOX;   Drug: FOLFIRI
3 Completed
Has Results
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Conditions: Ovarian Cancer;   Basal Cell Carcinoma;   Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib;   Drug: FOLFOX;   Drug: FOLFIRI;   Drug: Bevacizumab
4 Active, not recruiting Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas
Conditions: Basal Cell Nevus Syndrome;   Gorlin's Syndrome
Interventions: Drug: GDC-0449;   Procedure: Aminolevulinic acid %20 topical solution + blue light
5 Completed GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
Condition: Recurrent Childhood Medulloblastoma
Interventions: Drug: vismodegib;   Other: laboratory biomarker analysis;   Other: pharmacological study
6 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
7 Completed GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: vismodegib;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
8 Completed
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib
9 Active, not recruiting GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Conditions: Adult Solid Neoplasm;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Other: Diagnostic Laboratory Biomarker Analysis;   Drug: Erlotinib Hydrochloride;   Drug: Gemcitabine Hydrochloride;   Drug: Vismodegib
10 Recruiting Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Conditions: Locally Advanced Basal Cell Carcinoma;   Skin Cancer;   Cutaneous Malignancy
Interventions: Drug: Vismodegib;   Radiation: Radiation therapy
11 Completed Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Vismodegib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
12 Active, not recruiting Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Condition: Malignant Neoplasm
Interventions: Other: Pharmacological Study;   Drug: Vismodegib
13 Completed
Has Results
Vismodegib for Treatment of Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Interventions: Drug: Vismodegib;   Drug: Placebo
14 Completed
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib 150 mg
15 Active, not recruiting Vismodegib in Treating Patients With Advanced Chondrosarcomas
Condition: Chondrosarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vismodegib
16 Active, not recruiting Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Condition: Recurrent Childhood Medulloblastoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vismodegib
17 Active, not recruiting Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Conditions: Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Vismodegib
18 Active, not recruiting Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Condition: Adult Medulloblastoma
Interventions: Other: Pharmacological Study;   Drug: Vismodegib
19 Completed Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft Part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Myxoid Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Mesenchymoma;   Adult Malignant Peripheral Nerve Sheath Tumor;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Adult Unclassified Pleomorphic Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Corpus Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma;   Unclassified Pleomorphic Sarcoma of Bone
Interventions: Drug: Gamma-Secretase Inhibitor RO4929097;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vismodegib
20 Not yet recruiting Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-versus-Host Disease
Condition: Progressive cGVHD
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vismodegib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years